Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + lenvatinib versus cabozantinib in advanced renal cell carcinoma after prior anti-PD-1/L1 therapy
2020-002075-35Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Belzutifan + lenvatinib with Cabozantinib (2 arms). Primary endpoint: Progression-Free Survival. Started Oct 2020; status: active.
02
Drugs
belzutifanlenvatinibcabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2020-002075-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002075-35.